CClinicalTrials.gg
Status unknownNCT01558713Updated Apr 27, 2012

Epidural Volume Extension and Intrathecal Use of Local Anesthetics in Cesarean Sections

A Phase 2/3 interventional study of Bupivacaine- Fentanyl - Normal Saline and Ropivacaine-Fentanyl-Normal Saline in Stillborn Caesarean Section, sponsored by University of Patras. Status unknown at 1 site in Greece. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-04-27.

Sponsored by University of Patras · Phase 2/3, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Apr 2012), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 2/3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

Intrathecal (i.t.) administration of isobaric bupivacaine, ropivacaine and levobupivacaine with addition of fentanyl for c-section either combined or not with administration of 10 ml of N/S 0,9% epidurally, in order to extent epidural space.Sensory and motor block profile, haemodynamics and side effects were assessed.

Read the detailed description

Parturients scheduled for elective caesarean section are randomly allocated to 6 groups: they receive double-blindly intrathecal isobaric bupivacaine 10 mg ( Group B), ropivacaine 15mg (Group R) , levobupivacaine 10mg (Group L) combined with 10 μg fentanyl and followed by epidural administration of 10 ml of N/S 0,9% respectively, and isobaric bupivacaine 10 mg ( Group BupivacaineF), ropivacaine 15mg (Group RopivacaineF) , and levobupivacaine 10mg (Group LevobupivacaineF) combined with 10 μg fentanyl without epidural administration of 10 ml of N/S 0,9%. Clinical endpoints are the sensory and motor block profile, haemodynamics (arterial pressure, heart rate) and side effects.

02

Conditions studied

  • Stillborn Caesarean Section

Browse trials for

Keywords

  • parturient
03

In context

Stillbirth

117 studies on the registry are indexed under Stillbirth; 33 are open to participants now.

This study's planned enrollment of 120 is below the median of 275 across 66 interventional studies indexed under Stillbirth.

Browse Stillbirth studies →

Lead sponsor

University of Patras is the lead sponsor of 69 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Elective cesarean section
  • ASA I-II

Exclusion criteria

Exclusion Criteria:

  • complicated pregnancy (i.e preeclampsia, eclampsia,arterial hypertension, diabetes mellitus)
  • abnormal fetal heart rate at the time of admission
  • body mass index > 35 kg/m2
  • height \<150cm and >185 cm
  • age \<18 yrs and >40 yrs
  • patients with contraindication to spinal anaesthesia( i.e anticoagulants)
  • ASA >III
  • intraoperative excessive bleeding
  • patients with previous psychiatric diseases
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Group BFS

    Group B: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%

    Drug: Bupivacaine- Fentanyl - Normal Saline

  • Active comparator
    Group RFS

    Group R : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%

    Drug: Ropivacaine-Fentanyl-Normal Saline

  • Active comparator
    Group LFS

    Group L: LEVO-BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%

    Drug: Levobupivacaine- Fentanyl- Normal Saline

  • Active comparator
    BupivacaineF

    Group BupivacaineF: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY

    Drug: Bupivacaine + Fentanyl

  • Active comparator
    RopivacaineF

    Group RopivacaineF : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY.

    Drug: Ropivacaine + Fentanyl

  • Active comparator
    LevobupivacaineF

    Group LevobupivacaineF: LEVO-BUPIVACAINE 0,5% (2ml) + 10μg FENTANYL(0,2ml) INTRATHECALLY.

    Drug: Levobupivacaine + Fentanyl

Interventions

  • DrugBupivacaine- Fentanyl - Normal Saline

    Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus

    Also known as: Bupivacaine hydrochloride 0.5% ( Marcaine Spinal, 5 mg/ml, AstraZeneca, Missisipi, ON, Canada), Fentanyl, 50μg/ml, Janssen-Cilag, Belgium, 0,9% Sodium Chloride Inj. BP, B.BRAUN Melsungen AG, German

  • DrugRopivacaine-Fentanyl-Normal Saline

    Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus

    Also known as: Ropivacaine 0.75% :( Naropeine 7.5mg/ml, AstraZeneca), Fentanyl: 50μg/ml, Janssen-Cilag, Belgium, 0,9% Sodium Chloride Inj. BP, B.Braun Melsungen AG

  • DrugLevobupivacaine- Fentanyl- Normal Saline

    Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus

    Also known as: Chirocaine 5mg/ml, Abbot Laboratories, Greece, Fentanyl, 50μg/ml, Janssen-Cilag, Belgium, 0,9% Sodium Chloride Inj. BP, B.Braun Melsungen AG

  • DrugBupivacaine + Fentanyl

    Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus

    Also known as: Bupivacaine hydrochloride 0,5% (Marcaine Spinal, 5mg/ml,AstraZeneca,Missisipi, ON, Canada), Fentanyl, 50μg/ml (Janssen-Cilag, Belgium)

  • DrugRopivacaine + Fentanyl

    Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus.

    Also known as: Ropivacaine 0,75% :(Naropeine 7,5mg/ml, AstraZeneca), Fentanyl 50μg/ml, Janssen-Cilag, Belgium.

  • DrugLevobupivacaine + Fentanyl

    Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus

    Also known as: Chirocaine 5mg/ml, Abbot Laboratories, Greece., Fentanyl 50μg/ml, Janssen-Cilag, Belgium.

06

What researchers measure

Primary outcomes

  1. Dermatomes of Sensory block

    Dermatomes of sensory block(pin prick test) are assessed every minute for the first 30 minutes after the intrathecal administration of local anesthetics and there after every 5 minutes until withdrawal of sensory block

    Time frame: up to 120 minutes average

  2. Motor block

    Motor block according to the Bromage scale are assessed every minute for the first 30 minutes after the intrathecal administration of local anesthetics and there after every 5 minutes until withdrawal motor block

    Time frame: up to 120 minutes average

Secondary outcomes

  1. Arterial Blood Pressure

    Measurements assesed every minute within the first 30 minutes after the intrathecal administration of local anesthetics and every 5 minutes until withdrawal of sensory and motor block

    Time frame: up to 120 minutes average

07

Study locations

1 of 1 sites recruiting
  • Department of Anesthesiology and Intensive Care Medicine, University Hospital of Patras
    Patras, Achaia 26504, Greece
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01558713
Lead sponsor
University of Patras
Responsible party
SKLAVOU CHRISTINA (Anesthesiologist- MD, University of Patras) — Principal investigator
First posted
Mar 20, 2012
Start date
Jan 2010
Primary completion
Sep 2012 (estimated)
Completion
Dec 2012 (estimated)
Last update
Apr 27, 2012

Study contacts

KRITON S FILOS, PROFESSOR
Contact
kritonfilos@yahoo.gr
+302613603341 ext. +30
CHRISTINA G SKLAVOU, MD
Contact
sklavou.christina@yahoo.gr
+302613603346
KRITON S FILOS, PROFESSOR
study chair · Department of Anesthesiology and Intensive Care Medicine, University Hospital of Patras
Christina G Sklavou, MD
principal investigator · Department of Anesthesia and Intensive Care Medicine, University Hospital of Patras

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion